DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the NEULAND LAB LTD. (NEULANDLAB) share price today?

NEULAND LAB LTD. (NEULANDLAB) is trading at ₹18,434 on the NSE, down 1.69% on the day. Source: DocStoX.

What is the PE ratio of NEULAND LAB LTD.?

NEULAND LAB LTD. has a price-to-earnings (PE) ratio of 65.0 in the Healthcare sector.

What is the market capitalisation of NEULAND LAB LTD.?

NEULAND LAB LTD. has a market capitalisation of approximately ₹23,643 crore.

NEULAND LAB LTD.

NEULANDLAB·NSE·Healthcare

₹18,434.00▼ -317.00 (-1.69%)

Healthcare · Pharmaceuticals

High-quality returns — 21% on equity

NIFTY 500NIFTY SMALLCAP 250

Day₹18055.00

₹18951.00

52W₹11500

₹2008981%

Open

₹18751.00

High

₹18951.00

Low

₹18055.00

Prev Close

₹18751.00

Volume

40.5K

VWAP

₹18304.10

Snapshot

Key fundamentals

Market Cap

₹23,643 Cr

P/E Ratio

64.97Expensive

P/B Ratio

13.37

EPS

₹283.71

Book Value

₹1461.00

ROE

21.40%Strong

ROCE

27.00%Efficient

Dividend Yield

0.17%

Debt / Equity

0.16Low

Face Value

₹10.00

52W High

₹20089.00

52W Low

₹11500.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹2,392

▼ 87.0%downside

Trading at ₹18,434 — 87% above our estimate

BearFair valueBull

₹2,033₹2,392₹3,054

/100

Business quality — Solid

Growth 89Profitability 85Efficiency 48Valuation 46

Plain English

Our view

High-quality returns — 21% on equity
Low debt relative to equity
Expensive — trades at 65× earnings

Strengths

Low debt relative to equity
Strong returns on equity (21%)
Capital is working hard (ROCE 27%)
Revenue compounding 19% over 3 years

Risks

Expensive — trades at 65× earnings
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

21% ROE fading to 12% over ~10 yrs, on ₹1461 book

₹2,208

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹3,054

Analyst target

No analyst coverage

—

Blended fair value₹2,392

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (21%)
Capital is working hard (ROCE 27%)
Revenue compounding 19% over 3 years
Profit growing 30% a year

Bear case

Expensive — trades at 65× earnings
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

65.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

21.4%Strong

Above 15% is considered healthy for Indian equities

ROCE

27.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.16Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹23,643 Cr

P/B

13.37

EPS

₹283.71

Div Yield

0.17%

What changed

Recent changes

Foreign investors-0.4% stake last quarter
Domestic institutions+1.1% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 65.0×

Growth

Strong

+19% rev CAGR

Profitability

Excellent

21.4% ROE

Financial health

Rock solid

D/E 0.16

Momentum

N/A

No technicals

Today

Trading activity

Delivery %42.4%

Turnover₹7417.19L Cr

Trades16,753

VWAP₹18304.10

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+19.3%

+16.6%

10Y

+14.8%

Profit

+30.4%

+35.1%

10Y

+29.7%

EPS

+30.6%

+35.2%

10Y

+24.9%

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 38.5% CAGR over last 5 years

Watch-outs

Cons

Stock is trading at 13.4 times its book value
Promoter holding has decreased over last 3 years: -3.50%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.44 pts; domestic institutions added 1.13 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

33%

Promoter

Promoters

32.6%0.00

Public

23.8%-0.47

FII / FPI

20.5%-0.44

DII

15.8%+1.13

Others

7.2%

Total shareholders

46,304+117 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter32.63%

FII20.46%

DII15.84%

Public23.84%

Others7.23%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

NEULAND LAB LTD. valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

NEULAND LAB LTD. peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare NEULAND LAB LTD. with peers

NEULAND LAB LTD. vs SUN PHARMACEUTICAL IND L NEULAND LAB LTD. vs DIVI S LABORATORIES LTD NEULAND LAB LTD. vs TORRENT PHARMACEUTICALS L NEULAND LAB LTD. vs APOLLO HOSPITALS ENTER. L NEULAND LAB LTD. vs ZYDUS LIFESCIENCES LTD NEULAND LAB LTD. vs CIPLA LTD

NEULAND LAB LTD.

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

NEULAND LAB LTD. valuation & research

NEULAND LAB LTD. peers in Healthcare

Compare NEULAND LAB LTD. with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions